Patents by Inventor Annmarie Louise Sabb
Annmarie Louise Sabb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7671056Abstract: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I?): wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I?).Type: GrantFiled: June 9, 2006Date of Patent: March 2, 2010Assignee: Wyeth LLCInventors: Magda Asselin, George Theodore Grosu, Annmarie Louise Sabb, Wayne Everett Childers, Lisa Marie Havran, Zhongqi Shen, James Jacob Bicksler, Dan Chaekoo Chong
-
Patent number: 7608626Abstract: Compounds of formula 1 or pharmaceutically acceptable salts thereof are provided: which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.Type: GrantFiled: October 27, 2005Date of Patent: October 27, 2009Assignee: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel
-
Patent number: 7297704Abstract: The present invention provides cycloalkylfused indole, benzothiophene, benzofuran, and indene derivatives, and methods for using them to, for example, treat, prevent and/or ameliorate central nervous system diseases by antagonizing 5-HT1A receptors and modulating serotonin levels.Type: GrantFiled: February 16, 2006Date of Patent: November 20, 2007Assignee: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel, Gary Paul Stack, Deborah Ann Evrard, Amedeo Arturo Failli, Lalitha Krishnan, Anita Wai-Yin Chan, Jianxin Ren, Charles J. Guinosso, Reinhardt Bernhard Baudy, Jean Yi-ching Sze, Yanfang Li, Charles John Stanton, III, Antonia Nikitenko
-
Patent number: 7098338Abstract: This invention provides compounds of formula I, wherein R is hydrogen or alkyl of 1–6 carbon atoms; R? is hydrogen, alkyl of 1–6 carbon atoms, acyl of 2–7 carbon atoms, or aroyl; R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1–6 carbon atoms, alkoxy of 1–6 carbon atoms, halogen, trifluoroalkyl, or trifluoroalkoxy of 1–6 carbon atoms; X is CR5R6 or a carbonyl group; R5 and R6 are each, independently, hydrogen or alkyl of 1–6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least two of R1, R2, R3, or R4 are not hydrogen; which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.Type: GrantFiled: December 1, 2003Date of Patent: August 29, 2006Assignee: WyethInventors: Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
-
Patent number: 6858604Abstract: This invention provides compounds of the formula: wherein R1 and R2 are each, independently, H, alkyl, cycloalkyl, —CH2-cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, or phenoyl or thiophenoyl; R3 and R4 are each, independently, H, alkyl or cycloalkyl; R5 is H or alkyl; R6 is H or; and the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods utilizing these compounds for the treatment or prevention of disorders including obsessive-compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.Type: GrantFiled: November 2, 2001Date of Patent: February 22, 2005Assignee: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel
-
Publication number: 20040229865Abstract: This invention provides compounds of formula I having the structure 1Type: ApplicationFiled: June 18, 2004Publication date: November 18, 2004Applicant: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel
-
Patent number: 6784172Abstract: This invention provides processes for synthesizing compounds of formula I: wherein R is H or alkyl; R1, R2 are H, alkyl, alkoxy, halogen, fluorinated alkyl, —CN, alkyl sulfonamide, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, or aroyl; R3 and R4 are H, alkyl or cycloalkyl; the dashed line indicates an optional double bond; as well as intermediates and pharmaceutically acceptable salts thereof.Type: GrantFiled: November 2, 2001Date of Patent: August 31, 2004Assignee: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel, Madelene Miyoko Antane, Panolil Raveendranath, Sreenivasulu Megati, Michael David Smith, James Albert Nelson
-
Patent number: 6777407Abstract: This invention provides compounds of the formulae: wherein: R1 is hydrogen, —C(O)CH3 or alkyl of 1-6 carbon atoms; R2 and R3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl, alkoxy of 1-6 carbon atoms, —CH2OH, fluoroalkyl, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, fluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, aryl, or aroyl; R4 and R5 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, fluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, fluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R6 and R7 are each independently hydrogen, C1-C6 alkyl or cycloalkyl; or a pharmaceutically acceptable salt thereof, as well as pharmaceutType: GrantFiled: November 2, 2001Date of Patent: August 17, 2004Assignee: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel, James Albert Nelson, Sharon Joy Rosenzweig-Lipson, Gregory Scott Welmaker, Joan Eileen Sabalski
-
Patent number: 6759405Abstract: This invention provides compounds of formula I having the structure wherein: R1 and R2 are H, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated, acyl, or aroyl; R3, R4 are H, alkyl, cycloalkyl or —CH2-cycloalkyl; R5 is H or alkyl; R6 is H or alkyl; and wherein the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, as well as methods for using these compounds to treat central nervous system disorders, including obsessive-compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.Type: GrantFiled: November 2, 2001Date of Patent: July 6, 2004Assignee: WyethInventors: Annmarie Louise Sabb, Robert Lewis Vogel
-
Publication number: 20040116437Abstract: This invention provides compounds of formula I, 1Type: ApplicationFiled: December 1, 2003Publication date: June 17, 2004Applicant: WyethInventors: Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
-
Patent number: 6706714Abstract: This invention provides compounds of formula I, R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR5R6 or a carbonyl group; R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen; which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eatinType: GrantFiled: September 16, 2002Date of Patent: March 16, 2004Inventors: Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
-
Publication number: 20030060468Abstract: This invention provides compounds of formula I, 1Type: ApplicationFiled: September 16, 2002Publication date: March 27, 2003Applicant: WyethInventors: Sharon Joy Rosenzweig-Lipson, Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
-
Patent number: 6503900Abstract: This invention provides [1,4]diazepino[6,7,1-jk]carbazole compounds of the formula: wherein: R1 and R2 are H, alkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, phenoyl or thiophenoyl; R3, R4, R5 and R6 are H, alkyl, cycloalkyl, alkoxy or cycloalkoxy; R7 is H or alkyl; R8 is H or alkyl; and the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, as well as methods and pharmaceutical compositions utilizing them for the treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.Type: GrantFiled: November 2, 2001Date of Patent: January 7, 2003Assignee: WyethInventors: Annmarie Louise Sabb, Gregory Scott Welmaker, Robert Lewis Vogel, Joan Eileen Sabalski
-
Patent number: 6476032Abstract: This invention provides compounds of formula I, wherein R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR5R6 or a carbonyl group; R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen; which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disordeType: GrantFiled: June 26, 2001Date of Patent: November 5, 2002Assignee: WyethInventors: Sharon Joy Rosenzweig-Lipson, Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
-
Publication number: 20020119966Abstract: This invention provides compounds of formula I having the structure 1Type: ApplicationFiled: November 2, 2001Publication date: August 29, 2002Applicant: American Home Products CorporationInventors: Annmarie Louise Sabb, Robert Lewis Vogel
-
Patent number: 5770734Abstract: R.sup.2 is H, alkyl of 1 to 6 carbon atoms, cyano, halo, nitro, amino or mono or dialkylamino in which the alkyl groups have 1 to 6 carbon atoms;R.sup.3 is H or alkyl of 1 to 6 carbon atoms;n is 1 to 5and R.sup.4 and R.sup.5 taken with the nitrogen atom to which they are attached are polymethylene of 4 to 6 carbon atoms, morpholino, pyrrolidin-2-on-1-yl, or a piperazin-1-yl moiety in the 4-position of which is H, alkyl of 1 to 6 carbon atoms or unsubstituted or substituted pyrimidinyl, pyridinyl, or pyrazinyl wherein the substituents are alkyl of 1 to 6 carbon atoms, alkoxyl of 1 to 6 carbon atoms, halo, cyano, nitro or trifluoromethyl and the pharmaceutically acceptable salts, hydrates and solvates thereof are M.sub.1 receptor agonists useful in treatment of dementias involving the cholinergic system.Type: GrantFiled: June 22, 1992Date of Patent: June 23, 1998Assignee: American Home Products CorporationInventor: Annmarie Louise Sabb
-
Patent number: 5750522Abstract: This invention provides compounds having the formula ##STR1## wherein R is azacycle or azabicycle;R.sub.1 is alkyl;R.sub.2 and R.sub.3 are each, independently, hydrogen, alkyl, alkoxy, or thioalkyl;n is 0-5;or a pharmaceutically acceptable salt thereof, which are useful in treating symptoms of cholinergic insufficiency involving cognitive disorders.Type: GrantFiled: July 12, 1996Date of Patent: May 12, 1998Assignee: American Home Products CorporationInventors: Annmarie Louise Sabb, William A. Kinney
-
Patent number: 5723468Abstract: The compound of the formula: ##STR1## where R.sub.1 is H, alkyl, perhaloalkyl, arylalkyl, alkenyl or alkynyl; R.sub.2 is H when R.sub.4 is other than H, and, when R.sub.4 is H, R.sub.2 is ##STR2## in which R.sub.5 is hydrogen or alkyl; R.sub.3 is hydrogen or halogen; R.sub.4 is H or ##STR3## X and Y are nitrogen and Z is carbon; n is 1 or 2; n.sub.1 is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt thereof are centrally active muscarinic agents.Type: GrantFiled: October 1, 1996Date of Patent: March 3, 1998Assignee: American Home Products CorporationInventors: Annmarie Louise Sabb, Michael Byron Webb